Sleep & breathing = Schlaf & Atmung最新文献

{"title":"Suicidality in adults with obstructive sleep apnea: A systematic review and Meta-Analysis.","authors":"Lauren R McCray, Anna J Kulangara, Shaun A Nguyen, Ted A Meyer, Robert F Labadie, Mohamed A Abdelwahab","doi":"10.1007/s11325-025-03462-5","DOIUrl":"10.1007/s11325-025-03462-5","url":null,"abstract":"<p><strong>Purpose: </strong>To assess relations between obstructive sleep apnea (OSA) and suicidality, measured by suicidal ideation, suicide attempts, and death by suicide.</p><p><strong>Methods: </strong>CINAHL, Cochrane Library, PubMed, PsycINFO and SCOPUS were searched from inception through June 24, 2024. Observational studies related to suicidality in adult OSA patients were included. Case reports and studies on central sleep apnea were excluded. Data were extracted and reviewed by two authors, with disagreements resolved by a third. Risk of bias was assessed with the Risk Of Bias In Non-randomized Studies - of Exposure for cohort studies and the Joanna Briggs Institute checklist for case-control and cross-sectional studies. Random effects meta-analyses (single means, proportions, and relative risks (RR)) were performed.</p><p><strong>Results: </strong>Fifteen studies (n = 1,438,523) were included: eight assessed suicidal ideation, two assessed suicide attempts, and six assessed death by suicide. The OSA group experienced a higher prevalence of suicidal ideation (12.4% [95% CI: 8.9%-16.3%] vs. 3.7% [95% CI: 1.9%-6.2%]), suicide attempts (1.5% [95% CI: 0.9%-2.2%] vs. 0.9% [95% CI: 0.1%-2.2%]), and death by suicide (0.3% [95% CI: 0.2%-0.4%] vs. 0.2% [95% CI: 0.1%-0.3%]) than controls (p < 0.001). The OSA group had a higher risk of suicidal ideation (RR = 1.8, 95% CI: 1.5-2.1) and death by suicide (RR = 1.9, 95% CI: 1.1-3.4) than the control group (p < 0.001).</p><p><strong>Conclusion: </strong>Suicidal ideation affects nearly 12% of patients with OSA, with close to 2% attempting suicide. Otolaryngologists should consider the risk of suicidality in these patients.</p>","PeriodicalId":520777,"journal":{"name":"Sleep & breathing = Schlaf & Atmung","volume":"29 5","pages":"301"},"PeriodicalIF":2.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Restorative effect of sequential 4-channel neuromuscular electrical stimulation in obstructive sleep apnea: a feasibility study.","authors":"Jiwoon Lim, Jee Hyun Suh, Seung U Lee, Won Jae Jo, Jaewon Lee, In-Young Yoon, Ju Seok Ryu","doi":"10.1007/s11325-025-03465-2","DOIUrl":"https://doi.org/10.1007/s11325-025-03465-2","url":null,"abstract":"<p><strong>Background: </strong>Dysphagia and sleep apnea share a common pathophysiology in that they involve the genioglossus muscle, which is important for chewing and swallowing. Sequential 4-channel neuromuscular electrical stimulation (NMES) based on the normal sequences of the suprahyoid and infrahyoid muscles has been shown to induce effective contractions of the genioglossus, styloglossus, and hyoglossus muscles. These effects may benefit patients with obstructive sleep apnea (OSA). This study aimed to evaluate the feasibility, safety, and efficacy of sequential 4-channel NMES in OSA.</p><p><strong>Methods: </strong>This prospective, single-center, pilot study enrolled patients aged 19-60 years with moderate to severe OSA. All participants performed home-based sequential 4-channel NMES for 60 min per session, 5 times a week, for 8 weeks during the daytime. Polysomnographic studies and clinical evaluations were conducted before and after the treatment. The primary outcome was the change in the Apnea-Hypopnea Index (AHI) from baseline. Secondary outcomes included polysomnography results such as the Oxygen Desaturation Index (ODI), snore events and percentage, saturation parameters, and the respiratory arousal index, as well as patient-reported outcomes including the Epworth Sleepiness Scale, the Korean version of the Pittsburgh Sleep Quality Index, Likert scales for satisfaction and discomfort, and the EQ-5D-5 L.</p><p><strong>Results: </strong>A total of ten participants completed the intervention and the follow-up evaluation. Eight weeks after the application of sequential 4-channel NMES, mean AHI reduced from 28.5 to 27.6 events/h, ODI decreased from 23.1 to 20.5 events/h, and snore percentage decreased from 38.1 to 32.3%, although none of these changes reached statistical significance. The mean duration and percentage of sleep time with oxygen saturation < 90% in polysomnography decreased from 38.7 min to 12.9 min (3.4%), also without statistical significance. And patient-reported outcomes improved after treatment, but these changes were not statistically significant.</p><p><strong>Conclusions: </strong>This study was the first to investigate sequential 4-channel NMES as a therapeutic option for patients with OSA. Given its feasibility and efficacy, 4-channel NMES warrants investigation in a larger, definitive trial in the future.</p>","PeriodicalId":520777,"journal":{"name":"Sleep & breathing = Schlaf & Atmung","volume":"29 5","pages":"300"},"PeriodicalIF":2.0,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting treatment success in pediatric mild-to-moderate OSA: real-world evidence from a model based on polysomnographic parameters.","authors":"Yuanming Wang, Chen Cheng","doi":"10.1007/s11325-025-03471-4","DOIUrl":"10.1007/s11325-025-03471-4","url":null,"abstract":"<p><strong>Background: </strong>Pediatric mild-to-moderate obstructive sleep apnea (OSA) is often treated with intranasal corticosteroids (INCS), but response rates vary. Identifying early predictors of treatment success may facilitate individualized therapy.</p><p><strong>Methods: </strong>We conducted a single-center, two-phase observational study to develop and validate a predictive model for INCS response in children aged 3-12 years with mild-to-moderate OSA, defined by a baseline apnea-hypopnea index (AHI) of 1.0-10.0 events/hour. The derivation cohort (n = 175) was retrospectively enrolled between 2019 and 2023. A prospective validation cohort (n = 60) was recruited between 2024 and 2025 using identical diagnostic and treatment protocols. All patients received standardized INCS therapy. Treatment response was defined as a ≥ 50% reduction in AHI along with improvement in clinical symptoms at 6-9 months follow-up.</p><p><strong>Results: </strong>Candidate predictors were extracted from baseline clinical and polysomnographic (PSG) parameters. Multivariable logistic regression was used to identify independent predictors. A predictive nomogram model was constructed based on these variables and externally validated in the prospective cohort. The model demonstrated good calibration and discrimination.</p><p><strong>Conclusion: </strong>This study presents a validated nomogram model based on PSG and clinical parameters to predict treatment response to INCS in pediatric OSA, supporting early decision-making and personalized treatment strategies.</p>","PeriodicalId":520777,"journal":{"name":"Sleep & breathing = Schlaf & Atmung","volume":"29 5","pages":"299"},"PeriodicalIF":2.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145153226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real world characteristics of central sleep apnea: a review of 29,000 consecutive patients undergoing polysomnography.","authors":"Sanjay R Patel, Michael V Genuardi, Rebecca DeSensi, Marat Fudim, Lars H Lund, Reena Mehra, Robin Germany, Scott McKane","doi":"10.1007/s11325-025-03446-5","DOIUrl":"10.1007/s11325-025-03446-5","url":null,"abstract":"<p><strong>Purpose: </strong>The characteristics of central sleep apnea (CSA) in real-world sleep referral populations remain poorly understood. We used the electronic health record of a large health system to understand the prevalence and risk factors for CSA among patients referred for sleep evaluation.</p><p><strong>Methods: </strong>We reviewed the records of 29,803 patients who underwent diagnostic polysomnography at six sleep laboratories over 14 years. A validated algorithm was used to extract polysomnographic results. CSA was defined as having an apnea hypopnea index (AHI) ≥ 5, a central apnea index ≥ 5, and a central apnea index > obstructive apnea index, while obstructive sleep apnea (OSA) was defined as AHI ≥ 5, obstructive apnea index ≥ 5, and obstructive apnea index > central apnea index.</p><p><strong>Results: </strong>A total of 583 patients had CSA (2.0% of overall cohort and 5.5% of those with AHI ≥ 5). Compared to those with OSA, older age and male sex were strong risk factors for CSA. The comorbidities most strongly associated with CSA included prior myocardial infarction and atrial fibrillation with adjusted odds ratios of 1.88 (95% confidence interval 1.28-2.74), and 1.85 (1.43-2.38). The prevalence of CSA in these groups was 7.1%, and 5.8% respectively. Of note, the importance of risk factors varied by sex.</p><p><strong>Conclusion: </strong>CSA was identified in 2.0% of patients undergoing diagnostic polysomnography in routine clinical practice, with risk varying substantially by demographics and comorbidities. Greater recognition of CSA risk can lead to more thoughtful evaluation to ensure accurate diagnosis and appropriate treatment.</p>","PeriodicalId":520777,"journal":{"name":"Sleep & breathing = Schlaf & Atmung","volume":"29 5","pages":"296"},"PeriodicalIF":2.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145153212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and treatments of Sleep-Disordered breathing in people with down syndrome: A narrative review.","authors":"Hiroyuki Sawatari, Akiko Chishaki, Shin-Ichi Ando","doi":"10.1007/s11325-025-03447-4","DOIUrl":"https://doi.org/10.1007/s11325-025-03447-4","url":null,"abstract":"<p><strong>Purpose: </strong>Sleep-disordered breathing (SDB) is accompanied by adverse effects like neurocognitive disorder, cardiovascular disease, and mood disorder, which are also common in people with Down syndrome (DS). As SDB needs to be managed in people with DS, this review described the prevalence, risk factors, unusual sleep postures (USPs), and treatments regarding SDB in people with DS.</p><p><strong>Methods: </strong>This review included papers reporting on the prevalence, risk factors, and treatments of SDB in people with DS. MEDLINE, PubMed, Web of Science, and Scopus databases were searched up to March 2025. Case reports were excluded from this review.</p><p><strong>Results: </strong>The estimated prevalence of SDB in adults and children with DS ranges from 72.6 to 100.0% and 37.5-100.0%, respectively. Craniofacial hypoplasia, obesity, and congenital heart disease, which are common in people with DS, were reported as risk factors for SDB. USPs such as leaning forward and sitting positions were also associated with SDB. Non-invasive ventilation therapy including positive continuous airway pressure therapy was effective and tolerable in people with DS. Hypoglossal nerve stimulation therapy was also effective, but complications like tongue/oral pain or discomfort (11.9%) and rash at surgical site (9.5%) were reported.</p><p><strong>Conclusion: </strong>The prevalence of SDB is high in people with DS regardless of age and might be associated with characteristics of DS (craniofacial hypoplasia, obesity, and congenital heart disease). USPs might be an easy and useful screening tool for SDB in DS. Non-invasive ventilation therapy and hypoglossal nerve stimulation therapy would be effective and tolerable treatments in people with DS.</p>","PeriodicalId":520777,"journal":{"name":"Sleep & breathing = Schlaf & Atmung","volume":"29 5","pages":"297"},"PeriodicalIF":2.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145153204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tracking glymphatic dysfunction in isolated rapid eye movement sleep behavior disorder: a longitudinal neuroimaging study.","authors":"Jung-Ick Byun, Jun-Sang Sunwoo, Jung-Won Shin, Tae-Joon Kim, Jin-Sun Jun, Chul-Ho Sohn, Hongyoon Choi, Jung Hwan Shin, Han-Joon Kim, Won Chul Shin, Ki-Young Jung","doi":"10.1007/s11325-025-03479-w","DOIUrl":"https://doi.org/10.1007/s11325-025-03479-w","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate baseline diffusion tensor imaging along the perivascular space (DTI-ALPS) index differences between patients with isolated REM sleep behavior disorder (iRBD) who progressed to a neurodegenerative disease (iRBD-C) and those who did not (iRBD-NC), and to assess the longitudinal changes in the DTI-ALPS index.</p><p><strong>Methods: </strong>We prospectively studied a cohort of 48 iRBD patients (minimum three-year follow-up) and 20 age- and sex-matched Healthy controls. All participants underwent magnetic resonance imaging. The DTI-ALPS index was then calculated and its values were compared among the iRBD-C, iRBD-NC, and control groups. Twenty-nine iRBD patients and 5 controls were rescanned after a mean of 41 months, and during the total follow-up period (mean = 4.5 years), 14 patients converted.</p><p><strong>Results: </strong>The iRBD-C group showed significantly lower DTI-ALPS indices at baseline compared to the control group (left: p = 0.009; right: p = 0.019). However, there was no significant difference between the iRBD-NC group and the control group. Furthermore, the iRBD-C group showed a lower DTI-ALPS index in the right hemisphere than the iRBD-NC group (p = 0.013). The longitudinal analysis showed a reduction in the ALPS index in patients with iRBD bilaterally. The baseline DTI-ALPS index was associated with baseline and longitudinal changes in cognitive function scores.</p><p><strong>Conclusion: </strong>The baseline DTI-ALPS index may be a promising biomarker for predicting iRBD patients at risk for conversion to alpha-synucleinopathy. The decrease in the ALPS index observed over time may reflect progressive neurodegenerative processes.</p>","PeriodicalId":520777,"journal":{"name":"Sleep & breathing = Schlaf & Atmung","volume":"29 5","pages":"298"},"PeriodicalIF":2.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145153223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy of two types polysomnography in diagnosing and monitoring OSA patients at COVID-19 pandemic: a retrospective study.","authors":"Denise Fernandes Barbosa, Marcelo Corrêa Alves, Almiro José Machado","doi":"10.1007/s11325-025-03444-7","DOIUrl":"https://doi.org/10.1007/s11325-025-03444-7","url":null,"abstract":"<p><p>Sleep-related breathing disorders, including snoring and obstructive sleep apnea (OSA), impact on the quality of life and are linked to various comorbidities. We retrospectively analyzed thirty-seven dental medical records of patients aged 25-80 with snoring and OSA treated with a customized mandibular advancement device (MAD) with the gold-standard type-I polysomnography (PSG) and home test with type-IV (BIOLOGIX) for OSA monitoring in clinical practice during the COVID-19 pandemic, focusing on the clinical applicability. The metrics analyzed included the apnea-hypopnea index (AHI), oxygen desaturation index (ODI), heart rate, and oxygen saturation (SpO2). Statistical analysis revealed significant changes in four metrics and correlations between heart rate and ODI. Results suggest that type-IV PSG is a viable alternative for OSA monitoring, particularly during the COVID-19 pandemic when access to sleep labs was limited. The customized MAD effectively reduced AHI. Unlike type-I PSG, type-IV PSG has limited diagnostic; it does not provide comprehensive sleep metrics, which restricts its utility in complex cases. However, BIOLOGIX is a viable tool for monitoring patients in dental sleep medicine clinical practices. This study highlights the potential of type-IV PSG to enhance OSA management. Further research with larger samples is needed to refine its clinical application and improve predictive accuracy.</p>","PeriodicalId":520777,"journal":{"name":"Sleep & breathing = Schlaf & Atmung","volume":"29 5","pages":"294"},"PeriodicalIF":2.0,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145126988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Home-based sleep monitoring using a novel non-contact, radar-based biomotion sensor in adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.","authors":"Sarah Dietz-Terjung, Svenja Straßburg, Christoph Schöbel, Tim Schulte, Paul Dietz, Fatma Ezzahra Gahbiche, Jose Ortiz, Christian Taube, Gerhard Weinreich, Sivagurunathan Sutharsan, Matthias Welsner","doi":"10.1007/s11325-025-03451-8","DOIUrl":"10.1007/s11325-025-03451-8","url":null,"abstract":"<p><strong>Purpose: </strong>Cystic fibrosis (CF) is a life-limiting autosomal recessive disease often treated with triple CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor, ETI). Sleep disturbances are common in people with CF (pwCF). This study evaluated the Sleepiz One+, a non-contact radar-based biomotion sensor, for monitoring respiratory rate, heart rate, apnea-hypopnea index (AHI), and sleep quality in pwCF with ≥ 1 F508del allele during ETI therapy. The device's suitability for home monitoring of therapy success was also assessed.</p><p><strong>Methods: </strong>In a six-month observational study, 58 adult pwCF (2908 recordings) used the Sleepiz One + at home to collect longitudinal data on respiratory and sleep parameters during ETI therapy.</p><p><strong>Results: </strong>Significant reductions in respiratory rate and time in bed were observed after starting ETI, with respiratory rate decreases detectable within 1-5 days. Short-term respiratory rate increases corresponded with infections verified by medical records. Heart rate decreased non-significantly, and sleep efficiency improved modestly. AHI slightly decreased overall but increased in some patients, possibly linked to ETI-related weight gain.</p><p><strong>Conclusion: </strong>Sleepiz One + reliably tracked respiratory and sleep changes during ETI therapy in adult pwCF. It shows promise for early infection detection via respiratory rate monitoring, warranting further investigation.</p>","PeriodicalId":520777,"journal":{"name":"Sleep & breathing = Schlaf & Atmung","volume":"29 5","pages":"293"},"PeriodicalIF":2.0,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145126984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: \"association between obstructive sleep apnea and hearing loss among a cohort of emergency responders\".","authors":"Manuela Zaidan Osmo, Tathiana A Alvarenga, Bianca Camilo Schimenes, Sergio Tufik, Monica Levy Andersen","doi":"10.1007/s11325-025-03463-4","DOIUrl":"https://doi.org/10.1007/s11325-025-03463-4","url":null,"abstract":"","PeriodicalId":520777,"journal":{"name":"Sleep & breathing = Schlaf & Atmung","volume":"29 5","pages":"291"},"PeriodicalIF":2.0,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145126975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suvorexant for the treatment of sleep disorders in children with severe cerebral palsy.","authors":"Reiko Koichihara, Kenjiro Kikuchi, Hirokazu Takeuchi, Yuko Hirata, Ryuki Matsuura, Shin-Ichiro Hamano, Akira Oka","doi":"10.1007/s11325-025-03453-6","DOIUrl":"https://doi.org/10.1007/s11325-025-03453-6","url":null,"abstract":"<p><strong>Purpose: </strong>Sleep disturbances are frequent among children with severe cerebral palsy, leading to huge burden on caregivers. This study aimed to evaluate the efficacy and safety of suvorexant for treating sleep disorders in children.</p><p><strong>Methods: </strong>Sixteen patients, aged 2-16, with sleep disorders were administered with suvorexant. Patient characteristics, efficacy, and safety of suvorexant were retrospectively investigated from patients' charts, and the Athens Insomnia Scale (AIS) scores surveyed by caregivers were compared before and after administering suvorexant.</p><p><strong>Results: </strong>Suvorexant was effective in 13 of 16 patients (81%). Multiple sleep disturbance patterns were observed in all patients. Suvorexant was effective in 81% (n = 13/16) of sleep maintenance disorders, 77% (n = 10/13) of sleep onset disorders, 100% (n = 9/9) of early awakening disorders, and 91% (n = 10/11) of circadian rhythm sleep-wake disorders. The mean maintenance dose in effective cases was 0.3 mg/kg (IQR, 0.28-0.42). AIS scores revealed a significant decrease in all items and total scores, which decreased from a mean of 15.0 to 4.7. No major adverse events were observed.</p><p><strong>Conclusions: </strong>Our results suggest that suvorexant is safe and provides sufficient improvement in insomnia and circadian rhythm disorders in children with severe cerebral palsy, leading to improved quality of life.</p>","PeriodicalId":520777,"journal":{"name":"Sleep & breathing = Schlaf & Atmung","volume":"29 5","pages":"292"},"PeriodicalIF":2.0,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145126990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}